Prior to this, the industry was represented in the Sistema portfolio only by the biopharmaceutical Binnopharm, which also produces hepatitis B vaccine. After purchasing the OBL Pharm, President of Sistema Andrei Dubovskov said it was “unique opportunity” to create one of the leaders the growing market for pharmaceuticals ”by combining it with Binnopharm. AFK plans to complete the creation of the merged company, which will be called Alium, in 2019.
The acquisition of Synthesis and Biocom, if it takes place, is in keeping with Sistema’s pharmaceutical business development strategy, Shuliak believes. At the same time, the corporation’s market share will have to be increased solely by regaining it from competitors, he notes. According to DSM Group estimates, in the next five years, the Russian pharmaceutical market will grow to a maximum of 5% per year; in 2018 it reached 1.68 trillion rubles. (+ 2.6%), including 451 billion rubles. government procurement.